Retrospective Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Feb 7, 2018; 24(5): 623-630
Published online Feb 7, 2018. doi: 10.3748/wjg.v24.i5.623
Table 1 Demographic characteristics of the subjects
Patient characteristics (n = 412)n (%)
Gender, Female242 (58.74)
Race, White368 (89.3)
Age, mean ± SD49.88 ± 14.49
Smoking
Current smoker180 (43.69)
Ex-smoker27 (6.57)
Never smoker203 (49.27)
Surgery for CD1
First Ileocolic resection370 (89.80)
First Ileal resection26 (6.31)
Second Ileocolic resection152 (36.89)
Second Ileal resection13 (3.15)
Exposure to medication
Immunomodulators pre-T1105 (25.48)
Anti-TNF agent pre-T180 (19.41)
Immunomodulators pre-T2187 (45.39)
Anti-TNF agent pre-T2120 (29.13)
Table 2 Phenotypes by Montreal classification
n (%)
Age at diagnosis
A1 (≤ 16)56 (13.63)
A2 (17-40)296 (72.57)
A3 (> 40)60 (14.6)
Disease location
L1 ileal279 (67.71)
L2 colonic2 (0.485)
L3 ileocolonic131 (31.87)
L4 upper GI disease50 (12.17)
p perianal disease125 (30.41)
Disease behavior
B1 non-stricturing, non-penetrating35 (08.49)
B2 stricturing167 (40.63)
B3 penetrating197 (47.93)
Table 3 Values for serological assays
Serological assaysMean ± SDMedian (IQRs)Range
GM-CSF cytokine, pg/mL3.18 ± 8.611.28 (0.43-3.05)0.0052-136.5
GM-CSF Ab, mcg/mL10.64 ± 19.763.81 (0.93-11.01)0.08-241.2
ASCA IgA, U/mL95.21 ± 77.3867.51 (27.86-174.4)1.92-242.8
ASCA IgG, U/mL69.79 ± 41.0966.86 (31.76-104.2)3.17-158.1
Table 4 Risk factors at or after the initial Crohn’s disease surgery associated with time to the second Crohn’s disease surgery
Main effectsHR95%CIP valueFDR
Immunomodulators10.4860.306-0.7730.0020.026
GM-CSF Ab level3.4931.430-8.5380.0050.030
GM-CSF cytokine level2.4891.292-4.7960.0050.030
B2 disease behavior21.4150.517-3.8740.4910.624
B3 disease behavior30.4150.146-1.1760.0910.145
Smoking41.2860.277-5.9810.7430.800
ASCA IgG, U/mL1.3180.799-2.1740.2700.378
Age at diagnosis0.9830.963-1.0030.0940.145
Clostridium difficile infection0.0350.001-1.0920.0510.113
antiTNF-α51.2720.662-2.4470.4610.615
ATG16L1 polymorphism1.7930.982-3.2730.0520.113
IRGM polymorphism0.0920.004-2.2620.1360.201
ASCA IgA, U/mL0.9760.755-1.2620.8520.852
NOD2 polymorphisms1.1230.741-1.7020.5770.673
Interactions
GM-CSF Ab level and smoking0.6120.454-0.8250.0010.026
GM-CSF cytokine level and ATG16L10.6520.480-0.8850.0050.030
GM-CSF Ab level and ASCA IgG, U/mL0.8080.674-0.9680.0180.081
GM-CSF Ab level and ATG16L10.7190.538-0.9620.0230.081
B2 disease behavior and Clostridium difficile21.571.456-319.2710.0230.081
B2 disease behavior and smoking1.6010.318-8.0590.5600.673
B3 disease behavior and smoking5.1170.966-27.1410.0500.113
GM-CSF Ab level and Clostridium difficile2.8651.065-7.7150.0330.104
GM-CSF cytokine level and Clostridium difficile0.9020.325-2.5010.8400.852
Smoking and IRGM0.4060.145-1.1340.0790.145
ASCA IgG, U/mL and IRGM1.8670.908-3.8350.0830.145
GMCSF cytokine level and antiTNF-α0.7650.562-1.0410.0820.145
GM-CSF Ab level and antiTNF-α0.9410.703-1.2600.6760.757
GM-CSF cytokine level and ASCA IgA, U/mL0.8650.750-0.9970.0410.113